NCT07227311

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jan 14, 2026
Primary completion: Jul 10, 2030
Completion date: Jul 10, 2030
First posted: Nov 12, 2025
Last posted: Nov 12, 2025
Enrollment: 200
Arms / groups: 3 / —
Source: AACT · ctgov ingestion

Drugs studied

carfilzomib
bortezomib
pomalidomide
dexamethasone
belantamab mafodotin

Indications studied

Multiple Myeloma

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT07227311

Timeline

Sponsors

Drugs studied

Indications studied